$ORMP
ORAMED PHARMACEUTICALS INC.

2024 Q3 Form 10-Q Financial Statement

#000121390024068992 Filed on August 14, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $674.0K
YoY Change 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $847.0K $1.693M $2.644M
YoY Change -56.25% -35.97% -9.2%
% of Gross Profit
Research & Development $2.242M $1.442M $1.821M
YoY Change 134.27% -20.81% -80.16%
% of Gross Profit
Depreciation & Amortization $52.00K $54.00K $52.00K
YoY Change 4.0% 3.85% 246.67%
% of Gross Profit
Operating Expenses $2.242M $1.442M $4.465M
YoY Change -22.5% -67.7% -63.07%
Operating Profit -$3.089M -$3.135M -$3.791M
YoY Change 6.77% -17.3% -66.8%
Interest Expense -$15.42M $13.97M $2.478M
YoY Change -1966.83% 463.88% 608.0%
% of Operating Profit
Other Income/Expense, Net -$15.42M $14.23M $2.478M
YoY Change -3644.83% 474.41%
Pretax Income -$18.51M $10.84M -$1.313M
YoY Change 463.61% -925.44% -88.14%
Income Tax $1.133M $1.634M
% Of Pretax Income 15.08%
Net Earnings -$19.62M $9.212M -$1.194M
YoY Change 508.91% -871.52% -89.21%
Net Earnings / Revenue -177.15%
Basic Earnings Per Share -$0.48 $0.22 $0.03
Diluted Earnings Per Share -$0.48 $0.22 $0.03
COMMON SHARES
Basic Shares Outstanding 40.77M shares 40.63M shares 40.03M shares
Diluted Shares Outstanding 40.90M shares 41.59M shares 40.23M shares

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $142.3M $152.7M $7.101M
YoY Change -18.69% 2050.92% -80.39%
Cash & Equivalents $42.10M $84.75M $6.767M
Short-Term Investments $100.2M $67.98M $334.0K
Other Short-Term Assets $474.0K $533.0K $769.0K
YoY Change -32.29% -30.69% -19.73%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $142.8M $153.3M $151.0M
YoY Change -18.74% 1.52% 11.94%
LONG-TERM ASSETS
Property, Plant & Equipment $718.0K $765.0K $945.0K
YoY Change -22.21% -19.05% 120.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $21.07M $29.59M $3.531M
YoY Change -60.61% 738.12% -86.36%
Other Assets $30.00K $28.00K $26.00K
YoY Change 7.69% 13.04%
Total Long-Term Assets $22.31M $30.95M $5.344M
YoY Change -59.58% 479.21% -80.51%
TOTAL ASSETS
Total Short-Term Assets $142.8M $153.3M $151.0M
Total Long-Term Assets $22.31M $30.95M $5.344M
Total Assets $165.1M $184.2M $156.3M
YoY Change -28.5% 17.85% -3.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.995M $3.483M $828.0K
YoY Change 92.12% 320.65% -76.21%
Accrued Expenses $243.0K $250.0K $236.0K
YoY Change -19.0% 5.93% 1.29%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.273M $3.733M $1.067M
YoY Change -93.25% 249.86% -83.37%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $60.00K $60.00K $4.592M
YoY Change -98.67% -98.69% 61.92%
Total Long-Term Liabilities $4.286M $4.336M $4.592M
YoY Change -4.5% -5.57% 61.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.273M $3.733M $1.067M
Total Long-Term Liabilities $4.286M $4.336M $4.592M
Total Liabilities $9.559M $8.069M $5.659M
YoY Change -88.44% 42.59% -38.85%
SHAREHOLDERS EQUITY
Retained Earnings -$166.4M -$146.8M -$167.7M
YoY Change -2.61% -12.44% 13.69%
Common Stock $322.9M $323.9M $484.0K
YoY Change 0.89% 66815.91% 4.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $156.4M $177.1M $151.5M
YoY Change
Total Liabilities & Shareholders Equity $165.1M $184.2M $156.3M
YoY Change -28.5% 17.85% -3.68%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$19.62M $9.212M -$1.194M
YoY Change 508.91% -871.52% -89.21%
Depreciation, Depletion And Amortization $52.00K $54.00K $52.00K
YoY Change 4.0% 3.85% 246.67%
Cash From Operating Activities -$7.101M $2.076M -$2.634M
YoY Change 914.43% -178.82% -68.98%
INVESTING ACTIVITIES
Capital Expenditures $5.000K $0.00 $20.00K
YoY Change -83.33% -100.0% -200.0%
Acquisitions
YoY Change
Other Investing Activities -$34.25M $94.66M -$14.69M
YoY Change -54.38% -744.35% -241.48%
Cash From Investing Activities -$34.26M $94.66M -$14.71M
YoY Change -54.4% -743.47% -241.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.291M -30.55M 0.000
YoY Change -101.73% -100.0%
NET CHANGE
Cash From Operating Activities -7.101M 2.076M -2.634M
Cash From Investing Activities -34.26M 94.66M -14.71M
Cash From Financing Activities -1.291M -30.55M 0.000
Net Change In Cash -42.65M 66.18M -17.34M
YoY Change 3232.19% -481.58% -1026.5%
FREE CASH FLOW
Cash From Operating Activities -$7.101M $2.076M -$2.634M
Capital Expenditures $5.000K $0.00 $20.00K
Free Cash Flow -$7.106M $2.076M -$2.654M
YoY Change 873.42% -178.22% -68.67%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
us-gaap Revenues
Revenues
usd
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35813
dei Entity Registrant Name
EntityRegistrantName
ORAMED PHARMACEUTICALS INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-0376008
dei Entity Address Address Line1
EntityAddressAddressLine1
1185 Avenue of the Americas
dei Entity Address Address Line2
EntityAddressAddressLine2
Third Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
844
dei Local Phone Number
LocalPhoneNumber
967-2633
dei Security12b Title
Security12bTitle
Common Stock, par value $0.012
dei Trading Symbol
TradingSymbol
ORMP
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
40769027 shares
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
84753000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
9055000 usd
CY2024Q2 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1778000 usd
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
95279000 usd
CY2024Q2 us-gaap Short Term Investments
ShortTermInvestments
66206000 usd
CY2023Q4 us-gaap Short Term Investments
ShortTermInvestments
57713000 usd
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
533000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
537000 usd
CY2024Q2 us-gaap Assets Current
AssetsCurrent
153270000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
162584000 usd
CY2024Q2 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
2000 usd
CY2023Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
7000 usd
CY2024Q2 ormp Investments At Fair Value
InvestmentsAtFairValue
23723000 usd
CY2023Q4 ormp Investments At Fair Value
InvestmentsAtFairValue
51035000 usd
CY2024Q2 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
2345000 usd
CY2023Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1807000 usd
CY2024Q2 ormp Other Nonmarketable Equity Securities Noncurrent
OtherNonmarketableEquitySecuritiesNoncurrent
3524000 usd
CY2023Q4 ormp Other Nonmarketable Equity Securities Noncurrent
OtherNonmarketableEquitySecuritiesNoncurrent
3524000 usd
CY2024Q2 ormp Amounts Funded In Respect Of Employee Rights Upon Retirement
AmountsFundedInRespectOfEmployeeRightsUponRetirement
28000 usd
CY2023Q4 ormp Amounts Funded In Respect Of Employee Rights Upon Retirement
AmountsFundedInRespectOfEmployeeRightsUponRetirement
27000 usd
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
765000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
873000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
566000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
694000 usd
CY2024Q2 us-gaap Assets Noncurrent
AssetsNoncurrent
30953000 usd
CY2023Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
57967000 usd
CY2024Q2 us-gaap Assets
Assets
184223000 usd
CY2023Q4 us-gaap Assets
Assets
220551000 usd
CY2024Q2 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
3483000 usd
CY2023Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1609000 usd
CY2023Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
51013000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
325000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
250000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000 usd
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
3733000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
53214000 usd
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4000000 usd
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
4000000 usd
CY2024Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
29000 usd
CY2023Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
28000 usd
CY2024Q2 us-gaap Taxes Payable Current And Noncurrent
TaxesPayableCurrentAndNoncurrent
11000 usd
CY2023Q4 us-gaap Taxes Payable Current And Noncurrent
TaxesPayableCurrentAndNoncurrent
11000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
236000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
342000 usd
CY2024Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
60000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
63000 usd
CY2024Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4336000 usd
CY2023Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
4444000 usd
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.012
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.012
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
60000000 shares
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40628924 shares
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40628924 shares
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
40338979 shares
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
40338979 shares
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
488000 usd
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
485000 usd
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
323385000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
320892000 usd
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-146808000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-157556000 usd
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
177065000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
163821000 usd
CY2024Q2 us-gaap Minority Interest
MinorityInterest
-911000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-928000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
176154000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
162893000 usd
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
184223000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
220551000 usd
us-gaap Revenues
Revenues
1340000 usd
CY2023Q2 us-gaap Revenues
Revenues
674000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2621000 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6248000 usd
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1442000 usd
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1821000 usd
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
376000 usd
CY2023Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
192000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3476000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3715000 usd
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1693000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2452000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-6097000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-8999000 usd
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3135000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3791000 usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
853000 usd
CY2024Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
261000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
19322000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
4075000 usd
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
14234000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2478000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
12372000 usd
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4924000 usd
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10838000 usd
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1313000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1634000 usd
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1634000 usd
us-gaap Profit Loss
ProfitLoss
10738000 usd
us-gaap Profit Loss
ProfitLoss
-4924000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
9204000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1313000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-10000 usd
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-335000 usd
CY2024Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-8000 usd
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-119000 usd
us-gaap Net Income Loss
NetIncomeLoss
10748000 usd
us-gaap Net Income Loss
NetIncomeLoss
-4589000 usd
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
9212000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-1194000 usd
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.26
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.22
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.26
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.22
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40899275 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40144725 shares
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40959759 shares
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40225594 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41427849 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40144725 shares
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
41591007 shares
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40225594 shares
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
162893000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-2496000 usd
us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
27000 usd
us-gaap Profit Loss
ProfitLoss
10738000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
176154000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
151156000 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
2430000 usd
us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1893000 usd
us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
100000 usd
us-gaap Profit Loss
ProfitLoss
-4924000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
150655000 usd
CY2024Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
165721000 usd
CY2024Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1214000 usd
CY2024Q2 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
15000 usd
CY2024Q2 us-gaap Profit Loss
ProfitLoss
9204000 usd
CY2024Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
176154000 usd
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
150148000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
-1770000 usd
CY2023Q2 us-gaap Noncontrolling Interest Increase From Subsidiary Equity Issuance
NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance
50000 usd
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-1313000 usd
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
150655000 usd
us-gaap Profit Loss
ProfitLoss
10738000 usd
us-gaap Profit Loss
ProfitLoss
-4924000 usd
us-gaap Depreciation
Depreciation
110000 usd
us-gaap Depreciation
Depreciation
89000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3856000 usd
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
457000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-16719000 usd
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-820000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2523000 usd
us-gaap Share Based Compensation
ShareBasedCompensation
1993000 usd
ormp Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
1000 usd
ormp Gain On Amounts Funded In Respect Of Employee Rights Upon Retirement
GainOnAmountsFundedInRespectOfEmployeeRightsUponRetirement
2000 usd
ormp Accrued Interest On Shortterm Borrowings To Maturity
AccruedInterestOnShorttermBorrowingsToMaturity
-1463000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4000 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-620000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
1549000 usd
us-gaap Increase Decrease In Accounts Payable Related Parties
IncreaseDecreaseInAccountsPayableRelatedParties
-3328000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
5000 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-25000 usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1340000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1000 usd
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
6000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-3000 usd
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
5000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
600000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8183000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
4000000 usd
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
89919000 usd
ormp Proceeds From Shortterm Deposits
ProceedsFromShorttermDeposits
93650000 usd
ormp Proceeds From Shortterm Deposits
ProceedsFromShorttermDeposits
59500000 usd
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
2725000 usd
ormp Proceeds From Longterm Deposits
ProceedsFromLongtermDeposits
-5000 usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
35000000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
219000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
124653000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-27913000 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
2430000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
49550000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-49550000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2430000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000 usd
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-31000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
75698000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-33697000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9055000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
40464000 usd
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
84753000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6767000 usd
ormp Interest Received
InterestReceived
-6439000 usd
ormp Interest Received
InterestReceived
-2866000 usd
us-gaap Interest Paid Net
InterestPaidNet
2316000 usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
58000 usd
ormp Derecognition Of Rightofuse Asset
DerecognitionOfRightofuseAsset
-26000 usd
ormp Derecognition Of Lease Liability
DerecognitionOfLeaseLiability
23000 usd
us-gaap Nature Of Operations
NatureOfOperations
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>NOTE 1 - GENERAL:</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-align: justify; text-indent: 165.9pt"><b> </b></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>a.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Incorporation and Operations</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.1pt"> </p> <p style="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Oramed Pharmaceuticals Inc. (collectively with its subsidiaries, the “Company”, unless the context indicates otherwise), a Delaware corporation, was incorporated on April 12, 2002.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On March 18, 2021, Oravax Medical Inc. (“Oravax”) was established by the Company and others. The Company holds a 63% interest in Oravax. Consequently, the Company consolidates Oravax in its consolidated financial statements since that time. </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On January 11, 2023, the Company announced that the ORA-D-013-1 Phase 3 trial did not meet its primary and secondary endpoints. As a result, the Company terminated this trial and a parallel Phase 3, ORA-D-013-2 clinical trial. As these results are considered a triggering event, the Company evaluated all of its long lived assets which include fixed assets and operating lease right-of-use assets in the first quarter of 2023 and concluded that no impairment was required. The Company completed an analysis of the data from the ORA-D-013-1 Phase 3 trial and found that subpopulations of patients with pooled specific parameters, such as body mass index (BMI), baseline HbA1c, age, gender and body weight, responded well to oral insulin. These subsets exhibited an over 1% placebo adjusted, statistically significant, reduction in HbA1c. Based on this analysis, the Company is working on a protocol for a new Phase 3 clinical trial, which was submitted to the U.S. Food and Drug Administration (the “FDA”).</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">On January 22, 2024, the Company and its wholly-owned subsidiary, Oramed Ltd., entered into a joint venture agreement (the “JV Agreement”), with Hefei Tianhui Biotech Co., Ltd. (“HTIT Biotech”) and Technowl Limited, a wholly-owned indirect subsidiary of HTIT Biotech (“HTIT Sub” and together with HTIT Biotech, “HTIT”), pursuant to which, subject to the terms and conditions set forth in the JV Agreement, the parties will establish a joint venture (the “JV”), based on the Company’s oral drug delivery technology.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The JV will focus on the development and worldwide commercialization of innovative products based on the Company’s oral insulin and POD™ (Protein Oral Delivery) pipeline and HTIT’s manufacturing capabilities and technologies. The parties intend for the JV to use the protocol the Company recently submitted to the FDA to initiate a Phase 3 oral insulin trial in the United States.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company and HTIT will initially hold equal shares in the JV, with each owning 50% of the equity. The board of directors will initially consist of equal representation from HTIT and the Company. HTIT will contribute to the JV $70,000 in cash, while the Company will contribute $20,000 (comprised of $10,000 in cash and $10,000 in shares of the Company’s common stock that will be subject to certain registration rights) and will transfer intellectual property related to its oral insulin and POD™ technology, as well as other assets in the Company’s pipeline. HTIT will have an option to invest additional funds into the JV up to an aggregate amount of $20,000, thereby increasing its equity holdings and granting the right to increase its board representation.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The consummation of the JV Agreement is subject to and contingent upon the parties entering into additional agreements pursuant to the JV Agreement. There is no assurance that the parties will complete and sign these additional agreements.  </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p><table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 0.75in"> </td> <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>b.</b></span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Development and Liquidity Risks</b></span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">The Company is engaged in research and development in the biotechnology field for innovative pharmaceutical solutions, including an orally ingestible insulin capsule to be used for the treatment of individuals with diabetes, and the use of orally ingestible capsules for delivery of other polypeptides, and has not generated significant revenues from its operations. Following the termination of the ORA-D-013-1 and ORA-D-013-2 Phase 3 trials, the Company’s research and development activities have been significantly reduced while it conducts a strategic review process. As a result, the Company is currently incurring lower research and development and sales and marketing expenses.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Based on the Company’s current cash resources and commitments, the Company believes it will be able to maintain its current planned activities and the corresponding level of expenditures for at least the next 12 months.</p>
CY2023Q1 ormp Percentage Of Placebo Adjusted
PercentageOfPlaceboAdjusted
0.01 pure
CY2024Q2 us-gaap Cash
Cash
10000000 usd
ormp Joint Venture Aggregate Amount
JointVentureAggregateAmount
20000000 usd
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4206451 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3694057 shares
CY2024Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3993552 shares
CY2024Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
2345000 usd
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1807000 usd
us-gaap Business Exit Costs1
BusinessExitCosts1
3056000 usd
ormp Warrant Expire
WarrantExpire
2027-11-10
us-gaap Principal Transactions Revenue
PrincipalTransactionsRevenue
35000000 usd
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
16540000 usd
ormp Aggregate Unpaid Principal Balance
AggregateUnpaidPrincipalBalance
6071000 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1634000 usd
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
566000 usd
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
694000 usd
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
250000 usd
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
267000 usd
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
236000 usd
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
342000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
486000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
609000 usd
CY2024Q2 ormp Derecognized A Rightof Use Asset
DerecognizedARightofUseAsset
26000 usd
ormp Derecognition Of Lease Liability
DerecognitionOfLeaseLiability
23000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
132000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
282000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
218000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
222000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
137000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
120000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
18000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
10000 usd
CY2024Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
505000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
634000 usd
CY2024Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
486000 usd
CY2023Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
609000 usd
us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
118522 shares
ormp Repurchased Amount
RepurchasedAmount
277 usd
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Per Share Weighted Average Price Of Shares Purchased
ShareBasedCompensationArrangementByShareBasedPaymentAwardPerShareWeightedAveragePriceOfSharesPurchased
2.34
CY2024Q2 us-gaap Notes Payable Current
NotesPayableCurrent
usd
CY2024Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
usd
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
CY2023Q2 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
ormp Accrued Interest On Shortterm Borrowings To Maturity
AccruedInterestOnShorttermBorrowingsToMaturity
usd
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
usd
us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
usd
ormp Proceeds From Longterm Deposits
ProceedsFromLongtermDeposits
usd
us-gaap Proceeds From Sale Of Longterm Investments
ProceedsFromSaleOfLongtermInvestments
usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
usd
us-gaap Interest Paid Net
InterestPaidNet
usd
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
ormp Derecognition Of Rightofuse Asset
DerecognitionOfRightofuseAsset
usd
ormp Derecognition Of Lease Liability
DerecognitionOfLeaseLiability
usd
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001176309

Files In Submission

Name View Source Status
0001213900-24-068992-index-headers.html Edgar Link pending
0001213900-24-068992-index.html Edgar Link pending
0001213900-24-068992.txt Edgar Link pending
0001213900-24-068992-xbrl.zip Edgar Link pending
ea0210443-10q_oramed.htm Edgar Link pending
ea021044301ex10-1_oramed.htm Edgar Link pending
ea021044301ex10-2_oramed.htm Edgar Link pending
ea021044301ex31-1_oramed.htm Edgar Link pending
ea021044301ex31-2_oramed.htm Edgar Link pending
ea021044301ex32-1_oramed.htm Edgar Link pending
ea021044301ex32-2_oramed.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ormp-20240630.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
ormp-20240630_def.xml Edgar Link unprocessable
ormp-20240630_lab.xml Edgar Link unprocessable
ormp-20240630_pre.xml Edgar Link unprocessable
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
ea0210443-10q_oramed_htm.xml Edgar Link completed
ormp-20240630_cal.xml Edgar Link unprocessable